CRMD Sep 2024 8.000 call
- GlobeNewswire
CorMedix Inc. Announces CMS Grants Pass-Through Status to Defencath
BERKELEY HEIGHTS, N.J., June 06, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that the Center for Medicare & Medicaid Services (CMS) has determined that DefenCath® qualifies for pass-through status under the hospital Out-Patient Prospective Payment System (OPPS). Pass-through status provides for separate payment under Medicare Part B f
- GlobeNewswire
CorMedix Inc. Announces Commercial Agreement With Top Tier Dialysis Provider
BERKELEY HEIGHTS, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that it has entered into a multi-year commercial supply contract with a top tier midsized dialysis provider for the supply of DefenCath® (taurolidine and heparin). CorMedix received NDA approval of DefenCath® under the Limited Population Pathway for Antibacterial and Antifungal D
- Insider Monkey
CorMedix Inc. (NASDAQ:CRMD) Q1 2024 Earnings Call Transcript
CorMedix Inc. (NASDAQ:CRMD) Q1 2024 Earnings Call Transcript May 11, 2024 CorMedix Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, and welcome to the CorMedix First Quarter 2024 Earnings Conference Call [Operator Instructions]. Today’s conference call is […]
